Free tool
Rare disease stocks
We cover 68 companies grouped under the Rare disease theme. The median market value in the group is $6.86B. Across the group, the median move over the past trading day is +1.08%. 78% of the 65 with a 200-day average trade above it. Price change over the past year runs from −13.8% to +210.4% across the middle 80 percent of the group, with a median of +51.3%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
68 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| VX1.DE | Vertex Pharmaceuticals Incorporated | 469.95 EUR | +10.56% | +22.24% | +40.14% |
| VRTX34.SA | Vertex Pharmaceuticals Incorporated | 88.83 BRL | +19.14% | −85.56% | −83.17% |
| VRTX | Vertex Pharmaceuticals Incorporated | $552.85 | +15.42% | +22.28% | +42.14% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $554.44 | +1.12% | +23.31% | +42.39% |
| ARGX | argenx SE | $1,019.49 | +14.70% | +21.37% | +50.52% |
| A1RG34.SA | argenx SE | 209.16 BRL | +18.17% | +11.37% | +44.49% |
| 0HD2.L | Alnylam Pharmaceuticals, Inc. | $240.20 | −4.67% | −39.64% | −46.85% |
| ALNY | Alnylam Pharmaceuticals, Inc. | $240.08 | −13.76% | −40.01% | −45.88% |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | 200.50 EUR | −20.91% | −41.22% | −11.75% |
| A1LN34.SA | Alnylam Pharmaceuticals, Inc. | 61.14 BRL | −11.65% | −45.14% | −49.89% |
| INSM | Insmed Incorporated | $123.89 | +18.29% | −30.05% | −3.45% |
| ROIV | Roivant Sciences Ltd. | $36.47 | +5.04% | +66.30% | +213.32% |
| JAZZ | Jazz Pharmaceuticals plc | $260.23 | +1.88% | +50.29% | +108.87% |
| ASND | Ascendis Pharma A/S | $252.99 | −0.17% | +18.61% | +32.89% |
| BBIO | BridgeBio Pharma, Inc. | $80.40 | −4.42% | +2.77% | +70.01% |
| CORT | Corcept Therapeutics Incorporated | $123.57 | +35.61% | +223.48% | +79.56% |
| 0JAV.L | Insmed Incorporated | $125.32 | +0.69% | −28.09% | −6.25% |
| BMRN | BioMarin Pharmaceutical Inc. | $66.12 | +9.71% | +11.22% | +13.03% |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | 52.70 EUR | +2.73% | +10.68% | +2.09% |
| B1MR34.SA | BioMarin Pharmaceutical Inc. | 166.77 BRL | +12.08% | −0.14% | +6.36% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $88.88 | +3.92% | +31.11% | +329.16% |
| CYTK | Cytokinetics, Incorporated | $77.46 | −3.92% | +25.48% | +109.29% |
| IONS | Ionis Pharmaceuticals, Inc. | $63.57 | +13.60% | −20.21% | +52.01% |
| KYMR | Kymera Therapeutics, Inc. | $126.64 | +15.07% | +74.05% | +202.82% |
| ABVX.PA | ABIVAX Société Anonyme | 98.10 EUR | −9.83% | −14.70% | +42.59% |
| 0JDI.L | Ionis Pharmaceuticals, Inc. | $63.80 | +4.15% | −19.18% | +49.07% |
| PTGX | Protagonist Therapeutics, Inc. | $150.59 | +11.09% | +72.73% | +164.75% |
| 0HNC.L | BioMarin Pharmaceutical Inc. | $66.16 | +0.37% | +11.49% | +12.68% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $84.86 | +1.20% | +81.60% | +182.02% |
| IMVT | Immunovant, Inc. | $43.50 | +8.51% | +67.89% | +192.14% |
| 4151.T | Kyowa Kirin Co., Ltd. | 2,596.00 JPY | −2.26% | +3.26% | +3.09% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $113.35 | +6.80% | +7.94% | +14.26% |
| SRRK | Scholar Rock Holding Corporation | $58.25 | +19.05% | +36.10% | +74.77% |
| 0HI3.L | Arrowhead Pharmaceuticals, Inc. | $88.72 | +2.53% | +31.87% | +317.86% |
| ORKA | Oruka Therapeutics, Inc. | $101.82 | +12.88% | +260.17% | +601.72% |
| LQDA | Liquidia Corporation | $70.49 | −16.50% | +124.49% | +168.53% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $80.20 | +26.23% | +90.93% | +142.74% |
| PTCT | PTC Therapeutics, Inc. Common Stock | $73.47 | −3.07% | −4.26% | +49.03% |
| DNTH | Dianthus Therapeutics, Inc. | $112.11 | +7.29% | +182.54% | +378.90% |
| TVTX | Travere Therapeutics, Inc. | $67.01 | +18.23% | +69.56% | +288.91% |
| MIRM | Mirum Pharmaceuticals, Inc. | $98.08 | −14.12% | +25.63% | +36.58% |
| GRFS | Grifols, S.A. | $8.09 | +4.39% | −12.45% | −17.62% |
| DYN | Dyne Therapeutics, Inc. | $26.34 | +2.77% | +42.38% | +102.62% |
| EWTX | Edgewise Therapeutics, Inc. | $44.21 | +6.27% | +86.15% | +209.16% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $37.46 | +92.20% | +228.02% | +340.71% |
| MANE | Veradermics, Incorporated | $102.35 | −8.14% | +171.13% | +171.13% |
| CAMX.ST | Camurus AB (publ) | 609.50 SEK | −2.25% | −0.41% | −14.52% |
| CPRX | Catalyst Pharmaceuticals Inc | $31.49 | 0.00% | +36.03% | +52.72% |
| CLDX | Celldex Therapeutics, Inc. | $41.22 | +15.62% | +52.61% | +87.96% |
| IRON | Disc Medicine, Inc. | $82.41 | +10.45% | +4.20% | +38.71% |
| ARQT | Arcutis Biotherapeutics, Inc. | $24.86 | −10.70% | −14.28% | +58.44% |
| 0RD1.L | Camurus AB (publ) | 615.00 SEK | +0.61% | +0.29% | −13.50% |
| VRDN | Viridian Therapeutics, Inc. | $24.18 | +22.74% | −21.19% | +30.21% |
| PHVS | Pharvaris N.V. | $37.31 | +9.83% | +40.90% | +57.76% |
| RARE | Ultragenyx Pharmaceutical Inc. | $26.46 | −1.60% | +12.12% | −9.60% |
| TRVI | Trevi Therapeutics, Inc. | $17.95 | −0.94% | +50.97% | +146.57% |
| VERA | Vera Therapeutics, Inc. | $35.28 | +0.28% | −27.44% | +65.32% |
| NKTR | Nektar Therapeutics | $74.96 | +5.06% | +72.64% | +176.20% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $9.83 | +2.61% | +31.07% | +17.16% |
| MLYS | Mineralys Therapeutics, Inc. | $26.34 | −3.20% | −26.24% | +78.70% |
| 009420.KS | Hanall Biopharma Co., Ltd. | 63,300.00 KRW | +40.04% | +50.00% | +108.57% |
| COAG | Hemab Therapeutics Holdings, Inc. | $49.65 | −1.47% | +46.03% | +46.03% |
| AUPH | Aurinia Pharmaceuticals Inc. | $16.75 | +10.05% | +9.12% | +38.03% |
| ZBIO | Zenas BioPharma, Inc. | $33.77 | +2.89% | −2.12% | +103.93% |
| STOK | Stoke Therapeutics, Inc. | $33.46 | +14.16% | +8.28% | +77.32% |
| ADMA | ADMA Biologics, Inc. | $9.72 | +14.62% | −45.64% | −42.86% |
| PVLA | Palvella Therapeutics, Inc. | $148.24 | +4.56% | +47.83% | +195.71% |
| NEU.AX | Neuren Pharmaceuticals Limited | 22.51 AUD | +32.02% | +19.04% | +18.47% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.